Genotype-guided antiplatelet therapy for acute coronary syndrome percutaneous coronary intervention patients: A new standard of care?

Catheter Cardiovasc Interv. 2021 Apr 1;97(5):795-796. doi: 10.1002/ccd.29659.

Authors

Kellan E Ashley^{1

2}, William B Hillegass^{2

3}

Affiliations

¹ Departments of Interventional Cardiovascular Disease, University of Mississippi Medical Center, Jackson, Mississippi.
² Departments of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
³ Departments of Data Science, University of Mississippi Medical Center, Jackson, Mississippi.

PMID: 33851782
DOI: 10.1002/ccd.29659

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome* / drug therapy
Genotype
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Standard of Care
Treatment Outcome

Substances

Platelet Aggregation Inhibitors

Grants and funding

U54 GM115428/GM/NIGMS NIH HHS/United States